Kornimate/medical-research-clean huggingface dataset:
influence of duration since birth until admission to well-baby nursery on neonatal temperature at admission

Conditions: Hypothermia, Newborn

Summary: the investigators will collect the time interval from birth to arrival to wbn or nicu, the time interval from arrival to nurse admission, the first measured temperature, and the week of birth. the investigators will divide the newborn infants to three groups: infants born vaginally, infants born by regular cesarean section, and infants born by friendly cesarean section, and compare the groups.

introduction friendly cesarean section mimics normal vaginal delivery as the newborn is put on mother's chest immediately after delivery and cutting the umbilical cord, and the mother even breastfeeds the newborn infant, if she wishes to. friendly cesarean section is offered to the mother if there are no contraindications, such as general anesthesia, fetal distress, or prematurity. skin to skin contacts lasts for several minutes, as long as the mothers wish to, and depend on mothers' medical state, and newborns' medical state. in friendly cesarean section, the skin to skin contact technique includes putting the newborn on mother's chest, and covering them both by a blanket. yet, during cesarean section the mother is covered by a thin paper-like sterile sheet, and as the temperature in operating room is low, her skin cools gradually from the spinal anesthesia until actually delivering the newborn infant. so, although the newborn infant is put on the mother's chest and covered by a blanket, there is a possibility for it to develop hypothermia. literature about this issue is rare, so the investigators conducted a study to check this possibility. methods in hillel yaffe medical center nurses measure infants temperature on admission to well-baby nursery (wbn) or neonatal intensive care unit (nicu). admission is not always performed on arrival, due to other nurse-tasks, such as other newborn infants treatment, or breastfeeding education. the most measureable piece of data that characterize friendly cesarean section is the longer time interval from the birth until arrival to wbn or nicu. inclusion criteria: infants born within the time study interval. exclusion criteria: infants born at less than complete 35 gestational weeks, since there is no for offer friendly cesarean section for these births. the investigators will collect the time interval from birth to arrival to wbn or nicu, the time interval from arrival to nurse admission, the first measured temperature, and the week of birth. the investigators will divide the newborn infants to three groups: infants born vaginally, infants born by regular cesarean section, and infants born by friendly cesarean section, and compare the groups.

Eligibility criteria:
inclusion criteria: * all newborn infants exclusion criteria: * infants born after less than 35 complete gestational weeks

Keywords: hypothermia friendly cesarean section
efficacy of macroporous polytetrafluoroethylene mesh in laparoscopic hernia repair

Conditions: Hernia, Inguinal

Summary: inguinal hernia repair is one of the most commonly performed surgeries around the world. it accounts for approximately 75% of all abdominal wall hernias and presents a lifetime risk of 27% in males and 3% in females. since the modern concept of surgical hernia repair described by bassini in 1887, with the technique that bears his name, several techniques have been developed in the last century in order to improve surgical outcomes after inguinal hernia repair. different open repairs, such as anterior (shouldice, mcvay) or posterior (stoppa) approach were described and developed, until lichtenstein described the tension-free hernioplasty concept supported by the use of a prosthetic mesh to repair the hernia defect. notable improvements were observed with this technique in terms of recurrence, pain, and discomfort in comparison with previous tension repairs. considerable advantages over open repair have been obtained with the introduction of minimally invasive surgery to inguinal hernia repair, in terms of patient comfort and recurrence rates. regarding prosthetic material, meshes have evolved since the first dacron mesh used by lichtenstein. first generation meshes were manufactured using more material and for this reason they have been described as heavyweight meshes. new generation meshes have been designed with less material in order to diminish the inflammatory response and foreign body reaction, providing less chronic pain with similar recurrence rates than heavyweight meshes. the density (or weight) of the mesh, measured in g/m2, is inversely proportional to the size of the pore and lately it has been reported that one of the main aspects related to prosthetic materials is pore size. large pore meshes use less material, consequently they have been associated with a better tissue ingrowth. the large pore of lightweight meshes is conditioned by the less amount of material used. all previous studies compare both light and heavyweight polypropylene meshes but in order to get a proper comparison of the behavior of meshes in the inguinal region it is important to include the material and the pore size. the aim of our study is to compare patient-reported outcomes with the use of either a polytetrafluoroethylene (ptfe) large pore mesh (lp-ptfe) vs a small pore polypropylene mesh (sp-ppl).

patients fitted for laparoscopic bilateral inguinal hernia repair will be randomized to recieve one of both meshes on study in both inguinal sides.

Eligibility criteria:
inclusion criteria: * male patients * 20-80 years old * primary bilateral hernia exclusion criteria: * women * bmi \>35 * recurrent hernias * previous infraumbilical laparotomy * inguinoscrotal hernias
efficacy and safety of rc28-e versus aflibercept in diabetic macular edema

Conditions: Diabetic Macular Edema

Summary: the purpose of this study is to evaluate efficacy and safety of rc28-e compared with aflibercept in subjects with diabetic macular edema.


Eligibility criteria:
inclusion criteria: * documented diagnosed with type i or type ii diabetes mellitus. * hemoglobin a1c (hba1c) of less than or equal to (≤) 10% within 2 months prior to day 1. * ability and willingness to undertake all scheduled visits and assessments. * the study eye must meet the following requirements: * macular thickening secondary to diabetic macular edema (dme) involving the center of the fovea. * decreased visual acuity attributable primarily to dme, the best corrected visual acuity (bcva) 19 or more letters, 78 letters or less. exclusion criteria: * the study eye with high risk of proliferative diabetic retinopathy. * the macular edema of the study eye is mainly caused by other diseases or factors other than dme. * treatment with panretinal photocoagulation or macular laser within 3 months prior to day 1 to the study eye. * administration of ivt any other anti-vegf drugs in the study eye within 3 months and/or in the other eye within 7 days prior to day 1. * any intraocular long-acting or sustained release corticosteroid treatment (e.g., dexamethasone intravitreal implant) in the study eye within 6 months prior to day 1. * active intraocular or periocular infection or active intraocular inflammation in either eye. * the study eye with poorly controlled glaucoma. * a history of idiopathic or autoimmune related uveitis in either eye. * history of stroke (cerebrovascular accident) or myocardial infarction within 6 months prior to day 1. * uncontrolled blood pressure, defined as a systolic value greater than (\>)180 millimeters of mercury (mmhg) and/or a diastolic value \>100 mmhg while a patient is at rest. * currently pregnant or breastfeeding, or intend to become pregnant during the study. * any current or history of ocular disease other than dme that may confound assessment of the macula or affect central vision in the study eye. * any current ocular condition which, in the opinion of the investigator, is currently causing or could be expected to contribute to irreversible vision loss due to a cause other than dme in the study eye. * other protocol-specified inclusion/exclusion criteria may apply.
resistance exercise reduces the expression of inflammation and fibrosis associated genes in autoimmune myositis patients

Conditions: Myositis; Exercise

Summary: the aim of this study was to investigate the effects of physical exercise on gene expression in muscle biopsies from patients with chronic polymyositis or dermatomyositis

eight patients with polymyositis or dermatomyositis according to the bohan and peter criteria and who had all participated in a resistive exercise trial at karolinska university hospital, stockholm, sweden, were included in this study. patients were included if they had a disease duration more than 12 months and they had to have a stable, low disease activity and medication for three months before enrollment in the study. patients with inclusion body myositis were excluded as well as patients with co morbidities that contradicted vigorous exercise (severe osteoporosis with multiple fractures, malignant disease severe lung disease) or if they were physically active more than once a week. the median disease duration at time of study start was 4.5 years (range 2,7-29 year). all patients had been treated with glucocorticoids and other immunosuppressive therapies with some improvement of muscle function but with persisting muscle impairment. at time of study seven patients were still on immunosuppressive treatment, five were taking prednisone with a median dosage of 2.5 mg/day (range 0-6.25 mg/d). six patients were treated with azathioprine, one in combination with cyclosporine a, one patient was treated with methotrexate and one with ivig 2g/kg body weight every three months

Eligibility criteria:
inclusion criteria: * patients were included if they had a disease duration more than 12 months and they had to have a stable, low disease activity and medication for three months before enrollment in the study exclusion criteria: * patients with inclusion body myositis were excluded as well as patients with co morbidities that contradicted vigorous exercise (severe osteoporosis with multiple fractures, malignant disease severe lung disease) or if they were physically active more than once a week.

Keywords: microarray inflammtion fibrosis
incretin hormones in type 1 diabetes mellitus;effect of metformin treatment

Conditions: Type 1 Diabetes Mellitus

Summary: investigators aim is to conduct an rct to study the effect of adjunct metformin treatment to insulin monotherapy in patients with type 1 diabetes, targeting the intestinal incretin secretion. the patients will be randomly allocated to metformin or placebo treatment for 4 months

compared to the large armamentarium of antidiabetic agents for type 2 diabetes mellitus (t2dm), the insulinocentric therapeutic approach in type 1 diabetes mellitus (t1dm) has distracted the scientific perspective from the rise of novel therapies. insulin monotherapy has long overshadowed the overall hormonal dysregulation that demarcates t1dm . in specific, the significance of the gut-derived incretin hormones glp-1 (glucagon-like peptide 1) and gip (glucose-dependent insulinotropic peptide), which are implicated with glucose metabolism via the gut-pancreatic axis, has been merely addressed. investigators' goal in the current protocol is to delineate the glucoregulatory role of incretin hormones in t1dm and the therapeutic advantages of adjunct metformin treatment over insulin monotherapy. in the absence of such knowledge, the development of effective strategies to improve metabolic homeostasis and ameliorate complications in t1dm patients will remain problematic. the central hypothesis of the study is that metformin, as an incretin-secretagogue, will enhance postprandial incretin secretion in t1dm patients, which will be reflected in reduced glucagon secretion and improvement in glycemic volatility. mechanistic insight will be provided through changes in specific amino acids and metabolites patterns, chronic inflammation and the microbiome composition.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * t1dm (diagnosis of diabetes before the age of 35 years and insulin use within 1 year of diagnosis) * treatment with multiple daily insulin injections (mdi) or continuous subcutaneous insulin infusion (csii) exclusion criteria: * any cardiovascular disease within the last 3 months * nyha stage 3 or 4 heart failure * uncontrolled angina * liver failure \[ast\>135 iu/l or alt\>129iu/l (3 x the upper normal limit)\] • kidney failure or gfr\<60 ml/min/1.73m2 * gastrointestinal disease or gastroparesis * prior diagnosis of cancer within 2 years * other medication that affect glucose metabolism within the last 3 months (metformin, sglt2, glp-1 analogues, amylin analogues, systemic glucocorticosteroids) * untreated or uncontrolled thyroid disease * pregnancy or breastfeeding * alcohol consumption \> 2-drinks per day or other substance abuse

Keywords: metformin incretin hormones inflammation microbiome
muscle relaxants on efficacy of lma insertion

Conditions: Anesthesia Intubation Complication

Summary: the use of laryngeal mask airway (lma) is increasing in pediatric anesthesia because it provides lesser direct mechanical stimulation of the airway due to being placed above the larynx. however, lma insertion can be more difficult in children than in adults due to their unique characteristics of pediatric airway. neuromuscular blocking agents, so-called, muscle relaxants have long been used to facilitate insertion of airway devices. but there are pros and cons for the efficacy of muscle relaxants in lma insertion, and most studies were investigated in adults.


Eligibility criteria:
inclusion criteria: * children aged between 2 and 7 years of american society of anesthesiologists physical status (asa ps) i or ii who are planned to receive ophthalmic surgery under general anesthesia exclusion criteria: * refusal of consent * present uri or other respiratory symptoms * oro or facial anomaly * poor dental condition * who cannot open their mouth or limited mouth opening * when the tracheal intubation is definitely needed

Keywords: laryngeal mask airway children, preschool muscle relaxant
assessment of qol and outcomes with sbrt for rcc

Conditions: Renal Cell Carcinoma

Summary: stereotactic body radiotherapy (sbrt) is an emerging radiotherapy technique that precisely delivers high doses of radiation to tumours. it has been investigated as definitive treatment for an increasing variety of primary tumours including lung, liver, prostate, and now renal cell carcinoma (rcc). the principal aims of this study are to prospectively assess quality of life (qol) and oncologic outcomes in non-surgical patients who receive sbrt for the treatment of rcc.

there is an evolving body of literature that shows high rates of tumour control and minimal associated toxicities with sbrt to treat rcc. however, the majority of published evidence is retrospective in nature, and there is a scarcity of data on the impact on quality of life and cost-effectiveness of kidney sbrt. the principal aims of this multicentre study are to prospectively assess qol and oncologic outcomes in non-surgical patients who receive sbrt for the treatment of primary renal cell carcinoma. the study population will include 30 consecutive patients treated with kidney sbrt on a conventional linear accelerator (35-40 gy in 5 fractions) at the odette cancer centre, sunnybrook health sciences centre, university of toronto (occ) and the juravinski cancer center, hamilton health sciences centre, mcmaster university (jcc).

Eligibility criteria:
inclusion criteria: * patients ≥18 years old * medically inoperable or patient who refuses surgery * histologic diagnosis of rcc where possible, or radiologic evidence of growth on surveillance * lesion ≥2.5cm or recurrent lesion following local ablative therapy * written informed consent * participants must be able to understand the english-language or with the aid of a translator exclusion criteria: * ecog ≥3 * prior abdominal radiation

Keywords: rcc stereotactic body radiotherapy sbrt stereotactic ablative radiotherapy sabr
photodynamic therapy using aminolevulinic acid in treating patients with skin cancer

Conditions: Non-melanomatous Skin Cancer

Summary: rationale: photodynamic therapy uses a drug that becomes active when it is exposed to a certain kind of light. when the drug is active, tumor cells are killed. this may be an effective treatment against skin cancer. purpose: this phase ii trial is studying the side effects of photodynamic therapy using aminolevulinic acid and to see how well it works in treating patients with skin cancer.

objectives: * to determine the safety and efficacy of intralesional photodynamic therapy using aminolevulinic acid and non-coherent blue light in patients with nodular basal cell carcinoma. outline: patients undergo photodynamic therapy comprising intralesional injection of aminolevulinic acid followed by non-coherent blue light therapy over approximately 17 minutes. patients may undergo re-treatment with photodynamic therapy 8 weeks later. patients undergo photographic assessment of their skin lesions at baseline, 8 weeks, 16 weeks, and then at 1 and 2 years to evaluate healing time, clinical improvement, and side effects. patients undergo biopsies of their skin lesions at 16 weeks and then at 1 and 2 years to confirm histological clearance.

Eligibility criteria:
disease characteristics: * biopsy-proven basal cell carcinoma on the trunk or extremities * tumor size ≤ 2 cm in diameter patient characteristics: * willing and able to comply with all follow-up requirements * mentally competent * no active, localized, or systemic infections * not immunocompromised * no coagulation disorder * no photosensitivity or allergy to sunlight * not pregnant or nursing * no history of keloid formation * no history of cutaneous photosensitization, porphyria, hypersensitivity to porphyrins, or photodermatosis prior concurrent therapy: * no prior gold therapy * no prior radiotherapy to the trunk and extremities * more than 24 months since prior oral retinoids (e.g., isotretinoin or acitretin) or photosensitizing drugs (e.g., declomycin®) * more than 1 year since prior collagen or other injections, botox® injections, chemical peels, dermabrasion, or resurfacing procedures * more than 1 month since prior topical retinoid therapy * no concurrent aspirin or antioxidants * no concurrent anticoagulation medications

Keywords: basal cell carcinoma of the skin recurrent skin cancer
treatment of fistula in ano with autologous fatty tissue cells transplantation

Conditions: Fistula in Ano; Transsphincteric Anal Fistula

Summary: this is a prospective interventional study on the treatment of transsphincteric fistula in ano. after abdominal or thigh liposuction, fat was injected around the fistula tract that was then transected percutaneously with a sharp cannula and fat injected between and around the cut parts. the internal opening was closed with a suture. minimum follow up of 12 months is planed

the study is intended to be carried out at the department of surgery of uppsala university hospital, as a single-center study. all (consecutive) otherwise healthy patients between the ages of 18-70 who have been diagnosed with perianal fistula where attempts to close the fistula is considered appropriate are asked to participate. this is done by the examining physician at their visit at the outpatient clinic. these are either patients who already have a relieving seton or those who need to be revised and treated with a seton before final closure. they receive written information about the study plan and have time to think about it. if they choose to participate in the study, they are planed for a visit to one of the surgeons involved in the study and here get another opportunity to ask questions and then also sign an informed consent. this step can be adjusted as telephone contact due to the covid-19 pandemic. thereafter, they are included in the study. the participants are operated on only by the surgeons involved, all of whom have undergone practical training in how fat cell transplantation is carried out according to the standardized coleman method. the procedure itself then takes place as a day surgery operation at the samariter hemmet ( part of the surgical department, uppsala university hospital ) operating department and either as a one- or two-step procedure, depending on whether they have a relieving seton or not. the seton has to be placed sometime before the definitive fatty tissue procedure so that there is no sign of inflammation/infection. a 3- and 12-months follow up visit is then arranged. in these visits, the patients are examined for evaluation of the result, possible residual fistulas, and complications. wexner score and vas scale are filed in and saved in their patient files.

Eligibility criteria:
inclusion criteria: * verified perianal or rectovaginal fistula * healthy individuals that can be accepted for an elective operation with total anesthesia. * signed consent exclusion criteria: * patients under the age of 18 or over the age of 75 years * another disease that can affect the perianal are or the procedure * patients that are not able to understand and sign the consent themselves.
the role of lung ultrasound in the diagnosis of weaning -induced pulmonary edema

Conditions: Detecting the Number of B-lines in Lung Ultrasound and Its Accuracy in Diagnosis of Weaning Induced Pulmonary Oedema

Summary: the aim of the work is to 1. assess the incidence of weaning induced pulmonary adema(wipo). 2. assess the risk factors of wipo. 3. evaluate the role of lung ultrasound in detecting wipo during spontenous breathing trial(sbt). 4. detect the threshold of b-line increase (delta-b-lines) that provided the best diagnostic accuracy of wipo.


Eligibility criteria:
inclusion criteria: * the study will include patients on mechanical ventilation who will be suitable for spontaneous breathing trial (sbt). exclusion criteria: * patients with poor lung ultrasound window, history of cardiomyopathy, significant valvular disease (aortic or mitral insufficiency of grade ≥ 2, mild or severe aortic and mitral stenosis) will be excluded from the study.
live long walk strong (llws) rehabilitation program: what features improve mobility skills

Conditions: Mobility Limitation

Summary: this study is being performed to evaluate the efficacy of the live long walk strong rehabilitation program in veterans 50 years and older. this study will also examine the features of the program that contribute to improved gait speed.

due to covid-19, currently completed a virtual version of the llws intervention study. the investigators are currently recruiting for the original study design in-person. this study is a 4 year phase ii randomized clinical trial study design. this study will provide important information about the mechanisms that contribute to meaningful improvement in mobility, the benefits of a novel mode of physical therapy care, and the duration of treatment effect.

Eligibility criteria:
inclusion criteria: * veteran * aged 50 and older * community dwelling * ability to speak and understand english * usual gait speed 0.5 m/s- 1.0 m/s activity modifications and access to telehealth rehabilitation exclusion criteria: * presence of a terminal disease * a major medical problem, unstable chronic condition, or psychiatric disorder that interferes with safe and successful testing and training * myocardial infarction or major surgery in previous 3 months * planned major surgery * baseline short physical performance battery score less than 4 * use of a walker * modified mini mental status examination score less than or equal to 77 * presence of a significant disease specific impairment such as: * peripheral neurologic impairment * orthopedic impairment * visual impairment

Keywords: rehabilitation aging mobility skills